(1R,2S)-1-Amino-N-(cyclopropylsulfonyl)-2-vinylcyclopropanecarboxamide 4-methylbenzenesulfonate - CAS 1028252-16-5
Catalog: |
BB054894 |
Product Name: |
(1R,2S)-1-Amino-N-(cyclopropylsulfonyl)-2-vinylcyclopropanecarboxamide 4-methylbenzenesulfonate |
CAS: |
1028252-16-5 |
Synonyms: |
(1R,2S)-1-amino-N-(cyclopropylsulfonyl)-2-vinylcyclopropanecarboxamide 4-methylbenzenesulfonate; (1R,2S)-1-amino-N-cyclopropylsulfonyl-2-ethenylcyclopropane-1-carboxamide; 4-methylbenzenesulfonic acid; (1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-vinylcyclopropanaminium 4-methylbenzenesulfonate; (1R,2S)-1-Amino-N-(cyclopropylsulfonyl)-2-ethenylcyclopropanecarboxamide 4-methylbenzenesulfonate (1:1); (1R,2S)-1-Amino-N-(cyclopropylsulfonyl)-2-vinylcyclopropane-1-carboxamide 4-methylbenzenesulfonate |
IUPAC Name: | (1R,2S)-1-amino-N-cyclopropylsulfonyl-2-ethenylcyclopropane-1-carboxamide4-methylbenzenesulfonic acid |
Description: | (1R,2S)-1-Amino-N-(cyclopropylsulfonyl)-2-vinylcyclopropanecarboxamide 4-methylbenzenesulfonate acts as a reagent in the preparation, SAR of methoxyisoquinoline derivatives and discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection. |
Molecular Weight: | 230.28 + (172.20) |
Molecular Formula: | C9H14N2O3S·(C7H8O3S) |
Canonical SMILES: | CC1=CC=C(C=C1)S(=O)(=O)O.C=CC1CC1(C(=O)NS(=O)(=O)C2CC2)N |
InChI: | InChI=1S/C9H14N2O3S.C7H8O3S/c1-2-6-5-9(6,10)8(12)11-15(13,14)7-3-4-71-6-2-4-7(5-3-6)11(8,9)10/h2,6-7H,1,3-5,10H2,(H,11,12)2-5H,1H3,(H,8,9,10)/t6-,9-/m1./s1 |
InChI Key: | WILXYULVXUTJDF-SOWVLMPRSA-N |
GHS Hazard Statement: | H302 (25%): Harmful if swallowed [Warning Acute toxicity, oral] |
Precautionary Statement: | P260, P264, P270, P280, P301+P317, P301+P330+P331, P302+P361+P354, P304+P340, P305+P354+P338, P316, P321, P330, P363, P405, and P501 |
Signal Word: | Danger |
Publication Number | Title | Priority Date |
CN-111004630-A | Preparation method of inorganic perovskite quantum dot with fluorescence wavelength regulated and controlled by electronegative ligand | 20200109 |
EP-2914598-B1 | Hepatitis c virus inhibitors | 20121102 |
EP-2914613-A1 | Hepatitis c virus inhibitors | 20121102 |
EP-2914613-B1 | Hepatitis c virus inhibitors | 20121102 |
US-2015284409-A1 | Hepatitis C Virus Inhibitors | 20121102 |
US-2015329547-A1 | Hepatitis C Virus Inhibitors | 20121102 |
US-9334279-B2 | Hepatitis C virus inhibitors | 20121102 |
US-9598433-B2 | Hepatitis C virus inhibitors | 20121102 |
WO-2014070964-A1 | Hepatitis c virus inhibitors | 20121102 |
US-2015284391-A1 | Hepatitis c virus inhibitors | 20121019 |
Complexity: | 614 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 2 |
Defined Atom Stereocenter Count: | 2 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 402.09192877 |
Formal Charge: | 0 |
Heavy Atom Count: | 26 |
Hydrogen Bond Acceptor Count: | 7 |
Hydrogen Bond Donor Count: | 3 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 402.09192877 |
Rotatable Bond Count: | 5 |
Topological Polar Surface Area: | 160Ų |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Other Building Blocks
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS